Tenax Therapeutics Inc (TENX) Actualités

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Form 424B4 - Prospectus [Rule 424(b)(4)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering

CHAPEL HILL, N.C., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty...

Form EFFECT - Notice of Effectiveness

Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Over 40 sites (U.S. and Canada) have agreed to participate in the LEVEL study LEVEL is a randomized...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Once granted, this patent will: provide U.S. intellectual property (IP) protection until December 2040, and may...

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form 424B3 - Prospectus [Rule 424(b)(3)]